London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Who can join
60 and older, any sex, with Mild Cognitive Impairment. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Change in Global Cognition Assessed Using the ADASCog(13 and Plus Modalities).Primary· baseline and at 20 weeks (after interventions finalised)
Global cognition will be assessed using the cognitive section of the Alzheimer Disease Assessment Scale-plus EF+FA (ADAS-Cog-plus). This scale consists of 10 brief cognitive tests assessing memory, language, executive function, praxis, and instrumental activities of daily living. The ADAS-Cog has been a significant outcome measure in numerous trials with MCI and AD. The ADAS-Cog-plus has marked advantages as an outcome measure in MCI populations since incorporates items concerning executive function (EF) and functional abilities (FA). Scores in the ADASCog-plus (EF+FA) range from 0 to 90, with
Group
Value
95% CI
Exercises+CognitiveTraining+Vitamin D3
-2.42
± 0.70
Exercises+CognitiveTraining+Placebo D3
-2.14
± 0.73
Exercises+Control CogTraining+Vitamin D3
-0.39
± 0.69
Exercises+Control CogTraining+Placebo D3
-1.34
± 0.73
Placebo Exercise+Control Cog+Placebo D3
0.24
± 0.76
Change in Cognition Assessed as the CCNA Cognitive Battery.Secondary· baseline at 20 weeks (after interventions finalised)
The Canadian Consortium on Neurodegeneration in Aging (CCNA) has established a battery of neuropsychological test which will used as secondary outcomes e.g., ADAS-Cog-13, which is scored from 0 to 70, with higher scores indicating greater cognitive impairment.
Group
Value
95% CI
Exercises+CognitiveTraining+Vitamin D3
15.3
± 8
Exercises+CognitiveTraining+Placebo D3
14.5
± 6.1
Exercises+Control CogTraining+Vitamin D3
16.6
± 7.6
Exercises+Control CogTraining+Placebo D3
15.6
± 6.6
Placebo Exercise+Control Cog+Placebo D3
13.7
± 5.3
Adverse events — posted to ClinicalTrials.gov
Time frame: From baseline visit and up to 30 days after study participation has ended month 12 visit..
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The proposed SYNERGIC trial is uniquely designed to evaluate the effect of aerobic and progressive resistance training exercises, combined with cognitive training and Vitamin D3 supplementation, in cognition and mobility in older adults with Mild Cognitive Impairment (MCI).
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT06201013 — Vitamin D Treat-to-Target Strategy for Children With Overactive Bladder-Wet
· NA
· recruiting
NCT07460336 — Effects of Cofrogliptin on Beta-Cell Function in LADA Patients
· NA
· not yet recruiting
NCT07006714 — Preoperative Correction of Vitamin D Deficiency in Total Joint Arthroplasty (TJA)
· Phase 4
· active not recruiting
NCT07269223 — Oral Vitamin D3 Effect on Inflammatory Biomarkers in Ulcerative Colitis Patients
· NA
· recruiting
NCT07048860 — ICOPE INTENSE-K Pilot Study
· NA
· recruiting
Other recruiting trials for Mild Cognitive Impairment
Currently open trials in the same condition.
NCT05791994 — EVASION: Effect of VisuAl Stimulation on attentION
· NA
· recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
· Phase 1
· recruiting
NCT07220694 — Effects of Sabroxy® Supplementation on Insulin Resistance and Cognitive Function in Adults With Mild Cognitive Impairmen
· NA
· recruiting
NCT06983769 — CPAP vs MAD for OSA in Patients With Cognitive Impairment. A Randomized Clinical Trial
· NA
· recruiting
NCT07318038 — The Use of Rhythmic Light Therapy in Mild Cognitive Impairment
· NA
· recruiting
Other London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's trials
Trials by the same sponsor.
NCT07588711 — Transcutaneous Auricular Vagus Nerve Stimulation as a Treatment for Neuropathic Pain Following Spinal Cord Injury
· NA
· not yet recruiting
NCT07585292 — Transcutaneous Auricular Vagus Nerve Stimulation as a Treatment for Musculoskeletal Pain in Cerebral Palsy
· NA
· not yet recruiting
NCT07510906 — Evaluation of a Prostate-Targeted PET Imaging System (P-PET) for Detecting Prostate Cancer
· NA
· not yet recruiting
NCT03166072 — Health Education vs Meditation in Irreversible Age-Related Vision Loss Patients and Their Caregivers
· NA
· not yet recruiting
NCT06035809 — Sensory Motor Arousal Regulation Treatment (SMART) Study
· NA
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Last refreshed: 21 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02808676.